June 29, 2020 / 9:00 PM / 4 days ago

BRIEF-Seattle Genetics Announces Positive Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

June 29 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

* SEATTLE GENETICS - LOOK FORWARD TO DISCUSSING WITH FDA POTENTIAL SUBMISSION OF BLA TO SUPPORT ACCELERATED APPROVAL OF TISOTUMAB VEDOTIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below